22UA Fundamental Analysis - BIONTECH SE-ADR

Fundamental Rating

22UA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. While 22UA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, 22UA is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 22UA has reported negative net income.

22UA had a negative operating cash flow in the past year.

Of the past 5 years 22UA 4 years were profitable.

Of the past 5 years 22UA 4 years had a positive operating cash flow.

1.2 Ratios

The Return On Assets of 22UA (-2.68%) is better than 65.43% of its industry peers.

With a decent Return On Equity value of -3.09%, 22UA is doing good in the industry, outperforming 70.37% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-2.68%
ROE	-3.09%
ROIC	N/A

ROA(3y)13.87%

ROA(5y)21.46%

ROE(3y)16.07%

ROE(5y)27.17%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 85.62%, 22UA is doing good in the industry, outperforming 76.54% of the companies in the same industry.

22UA's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for 22UA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	85.62%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.1%

GM growth 5Y0.34%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

22UA does not have a ROIC to compare to the WACC, probably because it is not profitable.

22UA has more shares outstanding than it did 1 year ago.

The number of shares outstanding for 22UA has been increased compared to 5 years ago.

The debt/assets ratio for 22UA is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 6.08 indicates that 22UA is not in any danger for bankruptcy at the moment.

22UA's Altman-Z score of 6.08 is amongst the best of the industry. 22UA outperforms 81.48% of its industry peers.

22UA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.01, 22UA is in the better half of the industry, outperforming 77.78% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	6.08

ROIC/WACCN/A

WACC7.26%

2.3 Liquidity

22UA has a Current Ratio of 7.12. This indicates that 22UA is financially healthy and has no problem in meeting its short term obligations.

22UA has a better Current ratio (7.12) than 88.89% of its industry peers.

A Quick Ratio of 7.02 indicates that 22UA has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 7.02, 22UA belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.12
Quick Ratio	7.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

22UA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.92%.

The Revenue has been growing slightly by 3.70% in the past year.

The Revenue has been growing by 90.73% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-20.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-114.81%

Revenue 1Y (TTM)3.7%

Revenue growth 3Y-47.47%

Revenue growth 5Y90.73%

Sales Q2Q%22.02%

3.2 Future

22UA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.03% yearly.

Based on estimates for the next years, 22UA will show a small growth in Revenue. The Revenue will grow by 2.18% on average per year.

EPS Next Y-18.79%

EPS Next 2Y-8.96%

EPS Next 3Y-5.74%

EPS Next 5Y14.03%

Revenue Next Year3.96%

Revenue Next 2Y0.72%

Revenue Next 3Y1.18%

Revenue Next 5Y2.18%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 22UA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 22UA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as 22UA's earnings are expected to decrease with -5.74% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-8.96%

EPS Next 3Y-5.74%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for 22UA!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIONTECH SE-ADR

FRA:22UA (12/30/2025, 7:00:00 PM)

81.35

+0.8 (+0.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-03 2025-11-03/bmo

Earnings (Next)03-10 2026-03-10/amc

Inst Owners22.75%

Inst Owner ChangeN/A

Ins Owners2.11%

Ins Owner ChangeN/A

Market Cap19.56B

Revenue(TTM)3.15B

Net Income(TTM)-571.60M

Analysts80.71

Price Target119.29 (46.64%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)33.13%

Min EPS beat(2)21.85%

Max EPS beat(2)44.42%

EPS beat(4)4

Avg EPS beat(4)77.6%

Min EPS beat(4)18.78%

Max EPS beat(4)225.36%

EPS beat(8)5

Avg EPS beat(8)44.65%

EPS beat(12)9

Avg EPS beat(12)207.14%

EPS beat(16)12

Avg EPS beat(16)164.98%

Revenue beat(2)2

Avg Revenue beat(2)63.4%

Min Revenue beat(2)55.06%

Max Revenue beat(2)71.75%

Revenue beat(4)4

Avg Revenue beat(4)33.69%

Min Revenue beat(4)1.02%

Max Revenue beat(4)71.75%

Revenue beat(8)5

Avg Revenue beat(8)18.96%

Revenue beat(12)6

Avg Revenue beat(12)5.54%

Revenue beat(16)9

Avg Revenue beat(16)12.1%

PT rev (1m)-1.58%

PT rev (3m)5.05%

EPS NQ rev (1m)80.22%

EPS NQ rev (3m)97.78%

EPS NY rev (1m)31.31%

EPS NY rev (3m)33.34%

Revenue NQ rev (1m)-0.19%

Revenue NQ rev (3m)-14.3%

Revenue NY rev (1m)23.93%

Revenue NY rev (3m)29.35%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	6.2
P/FCF	N/A
P/OCF	N/A
P/B	1.06
P/tB	1.17
EV/EBITDA	N/A

EPS(TTM)-2.37

EYN/A

EPS(NY)-3.3

Fwd EYN/A

FCF(TTM)-4.55

FCFYN/A

OCF(TTM)-1.32

OCFYN/A

SpS13.11

BVpS76.84

TBVpS69.58

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-2.68%
ROE	-3.09%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	85.62%
FCFM	N/A

ROA(3y)13.87%

ROA(5y)21.46%

ROE(3y)16.07%

ROE(5y)27.17%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.1%

GM growth 5Y0.34%

F-Score3

Asset Turnover0.15

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	202.92%
Cap/Sales	24.68%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.12
Quick Ratio	7.02
Altman-Z	6.08

F-Score3

WACC7.26%

ROIC/WACCN/A

Cap/Depr(3y)277.19%

Cap/Depr(5y)250.97%

Cap/Sales(3y)12.34%

Cap/Sales(5y)11.09%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-20.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-114.81%

EPS Next Y-18.79%

EPS Next 2Y-8.96%

EPS Next 3Y-5.74%

EPS Next 5Y14.03%

Revenue 1Y (TTM)3.7%

Revenue growth 3Y-47.47%

Revenue growth 5Y90.73%

Sales Q2Q%22.02%

Revenue Next Year3.96%

Revenue Next 2Y0.72%

Revenue Next 3Y1.18%

Revenue Next 5Y2.18%

EBIT growth 1Y-6.17%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year36.38%

EBIT Next 3Y13.64%

EBIT Next 5Y19.79%

FCF growth 1Y-123.34%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-105.92%

OCF growth 3Y-38.43%

OCF growth 5YN/A

BIONTECH SE-ADR / 22UA.DE FAQ

What is the ChartMill fundamental rating of BIONTECH SE-ADR (22UA.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 22UA.DE.

What is the valuation status for 22UA stock?

ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (22UA.DE). This can be considered as Overvalued.

Can you provide the profitability details for BIONTECH SE-ADR?

BIONTECH SE-ADR (22UA.DE) has a profitability rating of 3 / 10.

What is the financial health of BIONTECH SE-ADR (22UA.DE) stock?

The financial health rating of BIONTECH SE-ADR (22UA.DE) is 6 / 10.

BIONTECH SE-ADR (22UA.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BIONTECH SE-ADR / 22UA.DE FAQ

What is the ChartMill fundamental rating of BIONTECH SE-ADR (22UA.DE) stock?

What is the valuation status for 22UA stock?

Can you provide the profitability details for BIONTECH SE-ADR?

What is the financial health of BIONTECH SE-ADR (22UA.DE) stock?